176 related articles for article (PubMed ID: 22789767)
1. Exenatide for once-weekly administration.
Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
3. Exenatide once weekly in type 2 diabetes mellitus.
Bischoff LA; Jabbour SA; Miller JL
Expert Opin Pharmacother; 2011 Jun; 12(8):1297-1303. PubMed ID: 21548720
[No Abstract] [Full Text] [Related]
4. Once-weekly exenatide: an extended-duration glucagon-like peptide agonist for the treatment of type 2 diabetes mellitus.
Minze MG; Klein MS; Jernigan MJ; Wise SL; Frugé K
Pharmacotherapy; 2013 Jun; 33(6):627-38. PubMed ID: 23553357
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Ryan GJ; Moniri NH; Smiley DD
Am J Health Syst Pharm; 2013 Jul; 70(13):1123-31. PubMed ID: 23784159
[TBL] [Abstract][Full Text] [Related]
6. Extended-release exenatide (Bydureon) for type 2 diabetes.
Med Lett Drugs Ther; 2012 Mar; 54(1386):21-3. PubMed ID: 22421818
[No Abstract] [Full Text] [Related]
7. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
Fonseca T; Clegg J; Caputo G; Norrbacka K; Dilla T; Alvarez M
J Med Econ; 2013 Jul; 16(7):926-38. PubMed ID: 23659201
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
[TBL] [Abstract][Full Text] [Related]
9. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus.
Murphy CE
Ann Pharmacother; 2012 Jun; 46(6):812-21. PubMed ID: 22669803
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials.
Doggrell SA
Expert Opin Pharmacother; 2011 Sep; 12(13):2055-67. PubMed ID: 21534885
[TBL] [Abstract][Full Text] [Related]
11. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
12. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
Malmenäs M; Bouchard JR; Langer J
Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
[TBL] [Abstract][Full Text] [Related]
13. Once-weekly glucagon-like peptide 1 receptor agonists.
Kalra S; Gupta Y
J Pak Med Assoc; 2015 Jul; 65(7):796-8. PubMed ID: 26160096
[TBL] [Abstract][Full Text] [Related]
14. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
Kern W
MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
[No Abstract] [Full Text] [Related]
15. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
16. Exenatide extended-release: a once-weekly option for patients with type 2 diabetes.
Anderson ZL; Clements JN
JAAPA; 2014 Jun; 27(6):44-6. PubMed ID: 24853156
[TBL] [Abstract][Full Text] [Related]
17. Hormone copycats.
Gebel E
Diabetes Forecast; 2012 Jun; 65(6):36, 38-9. PubMed ID: 22737769
[No Abstract] [Full Text] [Related]
18. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
Aroda VR; DeYoung MB
Postgrad Med; 2011 Sep; 123(5):228-38. PubMed ID: 21904106
[TBL] [Abstract][Full Text] [Related]
19. Targeting the incretin system in type 2 diabetes mellitus.
Potenza M; Rayfield EJ
Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
[TBL] [Abstract][Full Text] [Related]
20. [Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)].
Scheen AJ
Rev Med Liege; 2014 Apr; 69(4):214-9. PubMed ID: 24923102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
